This study demonstrates that the overexpression of NAT10 instead of the NAT10‐mutant, whose active enzyme site is silenced, could enhance the malignancy of 5637 cells, reinforcing the hypothesis that the acetylation activity of NAT10 is correlated with the degree of malignancy of BLCA. This evidence concerns the gene NAT10 and bladder transitional cell carcinoma.